Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma
Top Cited Papers
- 20 August 2007
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (24) , 3766-3773
- https://doi.org/10.1200/jco.2006.10.2871
Abstract
Purpose To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma...Keywords
This publication has 59 references indexed in Scilit:
- Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group StudyJournal of Clinical Oncology, 2007
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?European Journal Of Cancer, 2006
- Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinomaInternational Journal of Experimental Pathology, 2005
- Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaJournal of Clinical Oncology, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Epidermal Growth Factor Receptor in Undifferentiated Carcinoma of the NasopharynxThe Laryngoscope, 2004
- Mutations of the BRAF gene in human cancerNature, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989